
Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.
Michael Birrer, MD, PhD, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.
Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.






